Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 277-283

  Kamoshida, S ^a   Suzuki, M ^a   Shimomura, R ^a   Sakurai, Y ^a   Komori, Y ^a   Uyama, I ^a   Tsutsumi, Y ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Gastric cancer; p53; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADJUVANT CHEMOTHERAPY; ADULT; ANTIGEN RETRIEVAL; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846470426     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603546     Document Type: Article

References (38)

1. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR (1994) An evaluation of siz antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12
2. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR (1993) Immunohistological detection of p53 in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-476
3. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N, Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522
4. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cisplatinum. Clin Cancer Res 4: 1469-1474
5. Cascinu S, Graziano F, Ferro ED, Staccioli MP, Ligi M, Carnevali A, Muretto P, Catalano G (1998) Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83: 1917-1922
6. Hall PA, Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? Revisited!. J Pathol 172: 1-4
7. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K (1996) The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122: 360-365
8. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455
9. Harwood FG, Frazier MW, Krajewski S, Reed JC, Houghton JA (1996) Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene 12: 2057-2067
10. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R (2004) Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250
11. Ikeguchi M, Tatebe S, Kaibara N, Ito H (1997) Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur Surg Res 29: 396-402
12. Japanese Research Society for Gastric Cancer (1999) Japanese Classification of Gastric Carcinoma, 1st English edn, pp 101-104. Tokyo: Kanehara Shuppan
13. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412
14. Kamoshida S, Matsuoka H, Matsuyama A, Shimomura R, Maruta M, Tsutsumi Y (2003a) Reproducible and reliable immunohistochemical demonstration of thymidylate synthase in formalin-fixed, paraffin-embedded sections: Application of antigen retrieval in EDTA solution. Acta Histochem Cytochem 36: 115-118
15. L protein in colorectal cancer with preoperative peroral chemotherapy: TS as marker of unresponsiveness to 5-fluorouracil. Ann Cancer Res Ther 11: 73-94
16. INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol 34: 594-601
17. Kirsch DG, Kastan MB (1998) Tumor-suppressor p53: implication for tumor development and prognosis. J Clin Oncol 16: 3158-3168
18. Lenz H-J, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182
19. Leonard CJ, Canman CE, Kastan MB (1995) The role of p53 in cell-cycle control and apoptosis: Implications for cancer. In Important Advances in Oncology, DeVita V, Hellman S, Rosenberg SA (eds), pp 33-42. Philadelphia: J.B. Lippincott
20. Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, Bailly M, Chen T, Chu E (2002) Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta 1587: 174-182
21. Malet-Martino M, Martino R (2002) Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7: 288-323
22. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S (2004) Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 24: 807-813
23. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, Fukushima M (2000) Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 17: 653-658
24. Nabeya Y, Loganzo Jr F, Maslak P, Lai L, de Oliveira AR, Schwarts GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP (1995) The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 64: 37-46
25. Nakata B, Chung KH, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue T, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M (1998) p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 28: 595-598
26. Parkin DM, Laara E, Muir CS (1988) Estimates of the worldwide frequency of sixteen majors cancers in 1980. Int J Cancer 41: 184-187
27. Peters GJ, van der Wilt CL, van Groeningen CJ (1994) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 30A: 1408-1411
28. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM (2000) Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36: 916-924
29. Satomi D, Takiguchi N, Koda K, Oda K, Suzuki H, Yasutomi J, Ishikura H, Miyazaki M (2002) Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int J Oncol 20: 1167-1171
30. Schoffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15: 85-106
31. Shiao Y-H, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni Jr JF, Rice JM (2000) Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev 9: 631-633
32. Uchida K, Hayashi K, Kuramochi H, Takasaki K (2001) Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int J Oncol 19: 341-346
33. Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166: 329-330
34. Yeh KH, Cheng AL (2004) Recent advances in therapy for gastric cancer. J Formos Med Assoc 103: 171-185
35. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626-1631
36. Yonemura Y, Kinoshita K, Fujimura T, Fushida S, Sawa T, Matsuki N, Tanaka S, Kamata T, Takashima T, Miyazaki I (1996) Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 43: 1260-1272
37. Yoshida I, Sakurai Y, Komori Y, Tonomura S, Masui T, Shoji M, Nakamura Y, Imazu H, Uyama I, Ochiai M (2005) Successful down-staging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis. Report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy. Hepatogastroenterology 52: 978-984
38. Yukimoto K, Nakata B, Muguruma K, Yashiro M, Ohira M, Ishikawa T, Hino M, Hirakawa K (2001) Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int J Oncol 19: 373-378